Benchmark, the global aquaculture genetics, health and specialist nutrition firm, is selling its vaccine manufacturing facility in Braintree, United Kingdom to the independent medical business Cell and Gene Therapy Catapult (CGT Catapult) for a total of £16 million (€17.5 million/$20.3 million).
"Benchmark is delighted that the timing and conclusion of our vaccine strategy review coincides with the need to scale capabilities to manufacture human vaccines in response to COVID-19 and that the talented team at Benchmark will become part of this critical effort," said Trond Williksen, CEO of Benchmark.
